الفهرس | Only 14 pages are availabe for public view |
Abstract Introduction: Carcinoid tumours were first characterized in 1907 by Siegfried Oberndorfer, a German pathologist at the University of Munich, who coined the term karzinoide, or ”carcinoma-like”, to describe the unique feature of behaving like a benign tumor despite having a malignant appearance microscopically. The recognition of their endocrine-related properties were later described by Gosset and Masson in 1914, and these tumors are now known to arise from the enterochromaffin (EC) and enterochromaffin-like (ECL) cells of the gut. Some sources credit Otto Lubarsch with the discovery. Aim of the Work: The aim of this work is to review the recent advances in diagnosis and management of carcinoid tumors of gastrointestinal tract. Methodology: Carcinoid tumors are rare, slow growing neuroendocrine tumors arising from the enterochromaffin Cells disseminated throughout the gastrointestinal tract. Cells found throughout the crypts of Lieberkuhn of the gut, and bronchopulmonary systems. They secrete serotonin and serotonin precursors. The incidence rates were 2.47: 4.48 for men and 2.58: 3.98 for women per 100,000 populations per year. Carcinoids form intramural grey firm nodules, masses or they may protrude into the lumen as polypoid nodules. Conclusion: Most patients with carcinoid tumors seek treatment for metastatic disease. The prognosis for patients with these tumors is variable and related to the site of the primary tumor, the presence of metastatic disease, and time of diagnosis. Importantly, the most common cause of carcinoid syndrome is metastatic liver disease arising from a small bowel carcinoid tumor. For these patients, the prognosis is uniformly poor. |